Esophageal Microbiome Detection for Barrett's Cancer Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and treating Barrett's esophagus are inefficient, as only a small percentage of patients with the condition develop esophageal cancer, making it difficult to effectively stratify risk and optimize surveillance and treatment strategies.
Innovation Solution
A method involving obtaining biological samples from the esophagus, analyzing the microbiome using plasmid dilution verification or quantitative polymerase chain reaction (qPCR) to identify specific bacteria associated with Barrett's esophagus and esophageal cancer risk, and employing treatments such as esophagectomy, probiotic therapy, or increasing surveillance frequency based on microbiome analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If periodic surveillance endoscopy examinations are performed on all patients with Barrett's esophagus, then early detection of esophageal cancer is improved, but healthcare costs and patient burden increase significantly
Solution Approach 1:
The invention changes the parameter of surveillance strategy from uniform periodic endoscopy for all patients to risk-stratified surveillance based on microbiome analysis. By measuring bacterial presence/abundance and calculating risk scores, patients are divided into high-risk and low-risk groups, allowing surveillance intensity to be adjusted according to individual risk levels rather than applying the same costly protocol to everyone.
Solution Approach 2:
The invention applies local quality by tailoring surveillance intensity to individual patient characteristics (microbiome profile) rather than applying a uniform approach. High-risk patients receive intensive surveillance while low-risk patients receive reduced surveillance, optimizing resource allocation based on local (individual) risk characteristics.
2Loss of energy
If microbiome analysis is performed to stratify patients, then surveillance cost-effectiveness is improved, but diagnostic complexity increases
Solution Approach 1:
The invention replaces complex visual endoscopic assessment and histological analysis with microbiome-based diagnostic testing. Instead of relying on expensive and invasive procedures to assess risk, the system uses molecular detection of bacterial DNA/RNA, which can be processed more efficiently and at lower cost while providing objective risk stratification.
Solution Approach 2:
The invention uses molecular copies (DNA/RNA) of bacterial organisms as proxies for direct bacterial observation. By detecting and quantifying bacterial genetic material in esophageal samples, the system infers the presence and abundance of specific bacteria without requiring complex culturing or direct visualization techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate detection and stratification of Barrett's esophagus risk, allowing for tailored surveillance and treatment approaches, improving the cost-effectiveness of care by identifying high-risk patients.
Implementation Method 1
determining a microbiome in the biological sample by detecting the presence of bacteria by plasmid dilution verification or quantitative polymerase chain reaction (qPCR)
Data Source
AI summary
The present invention includes a method of detecting and treating a patient suspected of having Barrett's esophagus comprising: obtaining a biological sample from an esophagus of the patient; determining a microbiome in the biological sample by detecting the presence of bacteria by plasmid dilution verification or quantitative polymerase chain reaction (qPCR); wherein if the patient has a microbiome indicative of an increased risk of esophageal cancer threating the patient with at least one of: removing at least part of the esophagus, esophagectomy probiotic therapy, or chemically targeting elimination of bacteria indicative of an increased risk of esophageal cancer.